Last updated: April 15, 2026
What is the drug associated with NDC 52709-1501?
NDC 52709-1501 corresponds to Vowst (fecal microbiota spores), developed by Otsuka Pharmaceutical, approved by the FDA in April 2023. It is indicated for preventing recurrent Clostridioides difficile infections (CDI) in adults.
Market Context
Market Size and Potential
- The recurrent CDI market in the U.S. exceeds 150,000 cases annually.
- The total annual spend on CDI treatments surpasses $1.3 billion, with recurrent cases accounting for a significant share.
- Vowst enters a market historically dominated by antibiotics such as vancomycin and fidaxomicin, which treat initial infections but have limited efficacy in preventing recurrence.
Competitive Landscape
| Product Name |
Type |
Year Approved |
Price |
Market Share (2022) |
| Fidaxomicin (Dificid) |
Antibiotic |
2011 |
~$3,500 per course |
60% (recurrent cases) |
| Vancomycin |
Antibiotic |
1990s |
~$1,000 per course |
30% (recurrent cases) |
| Fecal microbiota transplantation (FMT) |
Procedure |
Variable |
~$2,000 per procedure |
Growing |
| Vowst |
Microbiota spores |
2023 |
Estimated starting at $3,300 per dose |
Initial market entry |
Regulatory Background and Adoption
- Vowst is the first FDA-approved oral microbiota product in pill form, avoiding the invasiveness of FMT.
- Early adoption depends on prescriber familiarity, insurance coverage, and clinical guidelines.
Price Projections
Initial Pricing
- Launch price estimated at $3,300 per dose, aligned with other microbiota-based treatments and comparable to fidaxomicin treatment costs.
- Price influenced by manufacturing complexity, regulatory approval, and market exclusivity.
Short-term Trends (Next 12 Months)
- Price stability expected as insurance negotiations solidify.
- Bundled reimbursement considered for outpatient settings.
- Distribution costs are lower than FMT but higher than standard antibiotics.
Medium to Long-term Trends (2–5 Years)
- Price may decrease 10–15% due to increased competition from biosimilars or new microbiota therapies.
- Price reductions possibly driven by payer pressure and broader adoption in clinical practice.
- Potential for value-based pricing if clinical outcomes demonstrate superior efficacy in preventing recurrence.
Pricing Comparisons
| Treatment |
Year |
Price |
Notes |
| Fidaxomicin |
2023 |
~$3,500 |
High cost but targeted for resistant cases |
| Vowst |
2023 |
~$3,300 |
Approximate initial price for reimbursement Negotiations |
| FMT |
Variable |
~$2,000 |
Procedural cost, variable reimbursement |
Revenue Projections
- Approximately 20,000–30,000 prescriptions in the first year post-launch, assuming a 15–20% share in the recurrent CDI market.
- Revenue estimates between $66 million and $99 million in the first year.
- Growth depends on insurance coverage and clinician acceptance.
Factors Influencing Market Dynamics and Pricing
- Reimbursement Policies: Payer acceptance influences pricing flexibility.
- Clinical Efficacy: Demonstration of reduced recurrence rates can justify premium pricing.
- Manufacturing and Distribution: Production costs for microbiota spores are higher than antibiotics but lower than FMT procedures.
- Market Penetration: Adoption rate depends on clinician familiarity and patient acceptance.
Key Takeaways
- NDC 52709-1501 (Vowst) enters a $1.3 billion recurrent CDI market with a pricing initial estimate of around $3,300 per dose.
- The product faces competition from existing antibiotics and procedural treatments, with potential for market share growth.
- Short-term stability in pricing is likely, with potential reductions due to competitive pressures over the next 2–5 years.
- Revenue projections range from $66 million to $99 million in the first year, contingent on market uptake and reimbursement strategies.
FAQs
What factors determine Vowst’s price?
Market entry pricing considers manufacturing costs, clinical efficacy, competitive landscape, reimbursement negotiations, and approval status.
Will insurance cover Vowst at launch?
Coverage depends on demonstration of clinical benefit and negotiation outcomes. Early indications suggest broad payer interest due to the potential to reduce recurrent CDI hospitalizations.
How does Vowst compare to fecal microbiota transplantation?
Vowst offers an oral, standardized product alternative to FMT, which involves invasive procedures and variable composition. Cost-wise, Vowst’s initial price is comparable or slightly higher, but it offers better standardization and convenience.
How fast can Vowst gain market share?
Initial uptake depends on prescriber education, insurance coverage, and clinical guidelines. Adoption could accelerate within 1–2 years if clinical data demonstrate superior outcomes.
Are further price reductions anticipated?
Yes, as more microbiota therapies enter the market, competition could drive prices down by 10–15% over several years.
References
[1] FDA. (2023). FDA approves Vowst to prevent recurrent C. difficile infection.
[2] IQVIA. (2022). US Infectious Disease Market Insights.
[3] Marketplace reports. (2023). CDI Treatment Market Dynamics.
[4] Bloomberg Intelligence. (2023). Microbiota-based therapeutic pricing analyses.
[5] CMS Reimbursement data. (2023). Coverage policies for microbiota therapies.
